<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="3-part\PMC7150983\results\search\disease\results.xml">
  <result pre="and have proven to be the most effective countermeasures against" exact="influenza" post="infection. Their efficacy has been largely evaluated by hemagglutinin"/>
  <result pre="activities have the potential for prophylactic and therapeutic treatment of" exact="influenza" post="infection. Inducing mAbs mediated Fc-effector functions could be a"/>
  <result pre="in Fc-effector functions, especially ADCC and their potential role in" exact="influenza" post="countermeasures. Considering the complexity of anti-influenza approaches, future vaccines"/>
  <result pre="to elicit antibodies with broad-spectrum protection via multiple protective mechanisms." exact="influenza" post="non-neutralizing monoclonal antibody antibody-dependent cellular cytotoxicity (ADCC) Fc effector"/>
  <result pre="belong to the family Orthomyxoviridae [2]. Of these four genera," exact="influenza" post="A virus causes the greatest mortality and is the"/>
  <result pre="is the most common cause of both seasonal and pandemic" exact="influenza" post="outbreaks. Influenza B virus can cause seasonal influenza while"/>
  <result pre="and pandemic influenza outbreaks. Influenza B virus can cause seasonal" exact="influenza" post="while the influenza C virus can infect children with"/>
  <result pre="outbreaks. Influenza B virus can cause seasonal influenza while the" exact="influenza" post="C virus can infect children with mild respiratory symptoms."/>
  <result pre="symptoms. Little is known about the impact of recently discovered" exact="influenza" post="D virus on human health [3,4]. Hemagglutinin (HA) and"/>
  <result pre="surface glycoproteins (Figure 1) involved in critical steps of the" exact="influenza" post="life cycle. The trimeric HA protein is comprised of"/>
  <result pre="the nucleus of infected cells [2]. After the newly assembled" exact="influenza" post="virus buds from the infected cell, HA on the"/>
  <result pre="display difference in antigenic properties. According to the antigenic difference," exact="influenza" post="A virus can divide into 18 HA (H1–H18) and"/>
  <result pre="responsible for the majority of death cases during the 2019–2020" exact="influenza" post="season [7]. Vaccination is the best countermeasure to prevent"/>
  <result pre="[7]. Vaccination is the best countermeasure to prevent and control" exact="influenza" post="[8]. Live attenuated, inactivated and recombinant HA vaccines are"/>
  <result pre="recombinant HA vaccines are the three types of licensed seasonal" exact="influenza" post="vaccines [9]. These vaccines conferred considerable protection in combating"/>
  <result pre="influenza vaccines [9]. These vaccines conferred considerable protection in combating" exact="influenza" post="by inducing antibodies that target HA. However, their efficacy"/>
  <result pre="is a mismatch between the vaccine strain and the circulating" exact="influenza" post="strain [8]. Therefore, the ultimate goal is to develop"/>
  <result pre="a universal vaccine that could confer long-lasting protection against multiple" exact="influenza" post="strains, including the drifted seasonal influenza viruses and antigenically"/>
  <result pre="long-lasting protection against multiple influenza strains, including the drifted seasonal" exact="influenza" post="viruses and antigenically distinct viruses. Several approaches are employed"/>
  <result pre="that nnAbs can also contribute to the vaccine-elicited protection against" exact="influenza" post="virus infection in vivo [20,21]. The protective mechanisms employed"/>
  <result pre="assists in the elimination of virus-infected cells and protects against" exact="influenza" post="virus infection in a mouse model [22]. Importantly, these"/>
  <result pre="that ADCC-mediated antibodies (ADCC-Abs) can be induced from monovalent inactivated" exact="influenza" post="A(H1N1) virus vaccine, high titers of ADCC-Abs can contribute"/>
  <result pre="that both ADCC-Abs and neutralizing antibodies can be elicited by" exact="influenza" post="vaccination [23]. The mechanism of the antibody-triggered Fc-effector functions"/>
  <result pre="to initiate apoptosis [27]. Together, these facilitate the elimination of" exact="influenza" post="virus-infected cells [28]. This Fc-receptor binding activity was also"/>
  <result pre="dengue virus (DENV) [52], West Nile virus (WNV) [53] and" exact="influenza" post="virus [16,17]. HIV infection remains a health issue on"/>
  <result pre="used to assess ADCC activities evoked by antibodies against the" exact="influenza" post="virus and HIV [77,78]. 3.4. ADCC Reporter Bioassay This"/>
  <result pre="available assay has been employed to quantify ADCC activities against" exact="influenza" post="infections [17,80,81,82,83,84]. 4. ADCC Induced by anti-HA Antibodies 4.1."/>
  <result pre="Nevertheless, low levels of stalk-specific B cells are detected in" exact="influenza" post="patients [86]. Furthermore, anti-stalk antibodies with broad neutralizing activity"/>
  <result pre="al. reported that HA stalk-binding human antibody, CR6261, neutralizes multiple" exact="influenza" post="subtypes from group 1 [95]. Corti et al. found"/>
  <result pre="fusion sub-domain of the HA stalk could bind and neutralize" exact="influenza" post="A viruses from both group 1 and group 2"/>
  <result pre="al. reported an HA stalk-binding antibody, CR9114, broad binding to" exact="influenza" post="A and B HAs and the antibody was able"/>
  <result pre="the antibody was able to confer protection against not only" exact="influenza" post="A virus infection, but also influenza B virus infection"/>
  <result pre="protection against not only influenza A virus infection, but also" exact="influenza" post="B virus infection in mice [89]. It should be"/>
  <result pre="essential to the membrane fusion, HA stalk-binding antibodies can disarm" exact="influenza" post="virus infectivity [96]. Headless HA and chimeric HA are"/>
  <result pre="incorporation of two anti-viral mechanisms has attracted substantial attention in" exact="influenza" post="vaccine design. Those HA stalk vaccine candidates were tested"/>
  <result pre="targets the vestigial esterase domain of HA head of the" exact="influenza" post="B virus [74]. In addition, the vestigial esterase domain"/>
  <result pre="can not only neutralize Yamagata, Victoria and earlier lineages of" exact="influenza" post="B viruses, but also inhibits the membrane fusion, virus"/>
  <result pre="viruses. However, this evaluation may be challenged by some emerging" exact="influenza" post="viruses that lack the ability to agglutinate red blood"/>
  <result pre="antibodies. 5. ADCC to Other Proteins in Influenza Virus Three" exact="influenza" post="proteins are expressed on the viral membrane; HA, NA,"/>
  <result pre="broadest reactive spectrum to a variety of neuraminidases ranging from" exact="influenza" post="A group 1 and group 2, to both influenza"/>
  <result pre="from influenza A group 1 and group 2, to both" exact="influenza" post="B virus lineages [113]. These antibodies exhibited multiple anti-viral"/>
  <result pre="provide critical insights for the development of novel therapeutics against" exact="influenza" post="virus infection. In addition to those proteins expressed on"/>
  <result pre="In addition to those proteins expressed on the viral surface," exact="influenza" post="nucleoprotein (NP) possesses highly conserved regions and is also"/>
  <result pre="(NP) possesses highly conserved regions and is also detected on" exact="influenza" post="virus-infected host cells surface [123,124]. This makes NP reachable"/>
  <result pre="host immune response against NP may participate in multi-mechanisms against" exact="influenza" post="infection. Cytotoxic T lymphocytes (CTL) can kill target cells"/>
  <result pre="elicit ADCC activity and these mAbs can be induced by" exact="influenza" post="vaccination and natural infection in children [20,128]. However, the"/>
  <result pre="design. 6. ADCC-Based Vaccine To tackle the threat posed by" exact="influenza" post="viruses, developing a universal vaccine that can induce broad"/>
  <result pre="emerging strains with pandemic potential is of heightening priority of" exact="influenza" post="research. Considerable effort has been focused on the development"/>
  <result pre="on the development of therapeutic agents and universal vaccines against" exact="influenza" post="virus infection in recent decades. Protective antibodies that bind"/>
  <result pre="have been isolated and characterized in the vaccine research. Most" exact="influenza" post="vaccinology studies aim to induce a high titer of"/>
  <result pre="which are capable of conferring broad and durable protection against" exact="influenza" post="virus infection, but nnAbs are less investigated. However, it"/>
  <result pre="an equally potential candidate for universal vaccines and therapeutics against" exact="influenza" post="infection. Therefore, Fc-dependent effector activities should be considered and"/>
  <result pre="considered and recognized when we evaluate the protective effects of" exact="influenza" post="therapeutic agents and vaccine candidates. The ADCC activity serves"/>
  <result pre="than classic neutralizing antibodies, defining a promising direction to universal" exact="influenza" post="vaccines. Various animal models are used to assess the"/>
  <result pre="that the ADCC-Abs induced by vaccination are capable of inhibiting" exact="influenza" post="virus shedding in cynomolgus macaques [130]. A study focusing"/>
  <result pre="cases in China and Australia suggested that antibodies from severe" exact="influenza" post="survivors were more likely to exhibit potent ADCC activity,"/>
  <result pre="ADCC activity, which highlights critical role of ADCC in combating" exact="influenza" post="virus infections [131]. ADCC represents a promising strategy for"/>
  <result pre="M2 or the internal proteins may confer protection against severe" exact="influenza" post="diseases, however, may not prevent viral infection since these"/>
  <result pre="Activity Augmenting ADCC activity is a novel research direction in" exact="cancer" post="research. Target cell killing activities triggered by ADCC mAbs"/>
  <result pre="addition of ADCC-promoting agents, which has attracted substantial attention in" exact="cancer" post="research [134,135]. Means of augmentation of these responses in"/>
  <result pre="cancer research [134,135]. Means of augmentation of these responses in" exact="cancer" post="research might shed light on influenza research as well."/>
  <result pre="of these responses in cancer research might shed light on" exact="influenza" post="research as well. Different strategies for enhancing ADCC were"/>
  <result pre="[138]. 8. Conclusions and Future Directions The protective efficacy of" exact="influenza" post="vaccines largely depends on the stimulation of neutralizing antibodies."/>
  <result pre="apparent that nnAbs also play a critical role in combating" exact="influenza" post="infection even though in vitro antiviral activity is not"/>
  <result pre="similar to what is seen with traditional neutralizing antibodies. No" exact="influenza" post="studies have reported ADCC-antibody escape mutants currently, but Chung"/>
  <result pre="(4)Designing antibodies with enhanced capacity to induce ADCC activities against" exact="influenza" post="infection should be pursued vigorously. As stated above, new"/>
  <result pre="above, new approaches are being developed to augment ADCC in" exact="cancer" post="research. These studies in cancer research may provide valuable"/>
  <result pre="developed to augment ADCC in cancer research. These studies in" exact="cancer" post="research may provide valuable insights into influenza research towards"/>
  <result pre="These studies in cancer research may provide valuable insights into" exact="influenza" post="research towards developing better vaccines or therapeutics to improve"/>
  <result pre="influenza research towards developing better vaccines or therapeutics to improve" exact="influenza" post="patient outcomes. Therefore, it would be beneficial to measure"/>
  <result pre="effect in humans. However, mice are not natural hosts of" exact="influenza" post="and influenza viruses causing human epidemics or pandemics typically"/>
  <result pre="humans. However, mice are not natural hosts of influenza and" exact="influenza" post="viruses causing human epidemics or pandemics typically replicate inefficiently"/>
  <result pre="collectively indicated that ADCC-Abs are associated with reduced shedding of" exact="influenza" post="viruses [16,130]. Considering the different expression patterns of FcγRs"/>
  <result pre="instrumental to examine the potential role of ADCC-Abs in combating" exact="influenza" post="virus infection in humans [143]. (6)It would be interesting"/>
  <result pre="M2e induced potent long-lasting immunity and full protection against divergent" exact="influenza" post="A viruses challenge in mice, indicating that the combination"/>
  <result pre="Linked to Seasonal Flu Each YearWHOGinevra, Switzerland2017 2.BouvierN.M.PaleseP.The biology of" exact="influenza" post="virusesVaccine200826Suppl. 4D49D5310.1016/j.vaccine.2008.07.03919230160 3.HauseB.M.CollinE.A.LiuR.HuangB.ShengZ.LuW.WangD.NelsonE.A.LiF.Characterization of a novel influenza virus in"/>
  <result pre="2.BouvierN.M.PaleseP.The biology of influenza virusesVaccine200826Suppl. 4D49D5310.1016/j.vaccine.2008.07.03919230160 3.HauseB.M.CollinE.A.LiuR.HuangB.ShengZ.LuW.WangD.NelsonE.A.LiF.Characterization of a novel" exact="influenza" post="virus in cattle and Swine: Proposal for a new"/>
  <result pre="in the Orthomyxoviridae familyMBio20145e00031-1410.1128/mBio.00031-1424595369 4.HauseB.M.DucatezM.CollinE.A.RanZ.LiuR.ShengZ.ArmienA.KaplanB.ChakravartyS.HoppeA.D.et al.Isolation of a novel swine" exact="influenza" post="virus from Oklahoma in 2011 which is distantly related"/>
  <result pre="from Oklahoma in 2011 which is distantly related to human" exact="influenza" post="C virusesPLoS Pathog.20139e100317610.1371/journal.ppat.100317623408893 5.ShtyryaY.A.MochalovaL.V.BovinN.V.Influenza virus neuraminidase: Structure and functionActa"/>
  <result pre="Structure and functionActa Nat.20091263210.32607/20758251-2009-1-2-26-32 6.TongS.ZhuX.LiY.ShiM.ZhangJ.BourgeoisM.YangH.ChenX.RecuencoS.GomezJ.et al.New world bats harbor diverse" exact="influenza" post="A virusesPLoS Pathog.20139e100365710.1371/journal.ppat.100365724130481 7.collab: CDCWeeklyU.S.Influenza Surveillance ReportKey Updates for"/>
  <result pre="10.MargineI.KrammerF.HaiR.HeatonN.S.TanG.S.AndrewsS.A.RunstadlerJ.A.WilsonP.C.AlbrechtR.A.Garcia-SastreA.et al.Hemagglutinin stalk-based universal vaccine constructs protect against group 2" exact="influenza" post="A virusesJ. Virol.201387104351044610.1128/JVI.01715-1323903831 11.KrammerF.PicaN.HaiR.MargineI.PaleseP.Chimeric hemagglutinin influenza virus vaccine constructs"/>
  <result pre="protect against group 2 influenza A virusesJ. Virol.201387104351044610.1128/JVI.01715-1323903831 11.KrammerF.PicaN.HaiR.MargineI.PaleseP.Chimeric hemagglutinin" exact="influenza" post="virus vaccine constructs elicit broadly protective stalk-specific antibodiesJ. Virol.2013876542655010.1128/JVI.00641-1323576508"/>
  <result pre="Influenza VirusesJ. Virol.2016904720473410.1128/JVI.03152-1526912624 14.JegaskandaS.ReadingP.C.KentS.J.Influenza-specific antibody-dependent cellular cytotoxicity: Toward a universal" exact="influenza" post="vaccineJ. Immunol.201419346947510.4049/jimmunol.140043224994909 15.Von HolleT.A.MoodyM.A.Influenza and Antibody-Dependent Cellular CytotoxicityFront. Immunol.201910145710.3389/fimmu.2019.0145731316510"/>
  <result pre="16.JegaskandaS.WeinfurterJ.T.FriedrichT.C.KentS.J.Antibody-dependent cellular cytotoxicity is associated with control of pandemic H1N1" exact="influenza" post="virus infection of macaquesJ. Virol.2013875512552210.1128/JVI.03030-1223468501 17.Asthagiri ArunkumarG.IoannouA.WohlboldT.J.MeadeP.AslamS.AmanatF.AyllonJ.Garcia-SastreA.KrammerF.Broadly Cross-Reactive, Nonneutralizing"/>
  <result pre="22.HuberV.C.LynchJ.M.BucherD.J.LeJ.MetzgerD.W.Fc receptor-mediated phagocytosis makes a significant contribution to clearance of" exact="influenza" post="virus infectionsJ. Immunol.20011667381738810.4049/jimmunol.166.12.738111390489 23.ZhongW.LiuF.WilsonJ.R.HolidayC.LiZ.N.BaiY.TzengW.P.StevensJ.YorkI.A.LevineM.Z.Antibody-Dependent Cell-Mediated Cytotoxicity to Hemagglutinin of"/>
  <result pre="neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against" exact="influenza" post="virus in vivoNat. Med.20142014315110.1038/nm.344324412922 30.WeinerL.M.SuranaR.WangS.Monoclonal antibodies: Versatile platforms for"/>
  <result pre="influenza virus in vivoNat. Med.20142014315110.1038/nm.344324412922 30.WeinerL.M.SuranaR.WangS.Monoclonal antibodies: Versatile platforms for" exact="cancer" post="immunotherapyNat. Rev. Immunol.20101031732710.1038/nri274420414205 31.SchroederH.W.Jr.CavaciniL.Structure and function of immunoglobulinsJ. Allergy"/>
  <result pre="of metastatic colorectal cancerClin. Ther.200830143010.1016/j.clinthera.2008.01.01418343240 39.KrammerF.The human antibody response to" exact="influenza" post="A virus infection and vaccinationNat. Rev. Immunol.20191938339710.1038/s41577-019-0143-630837674 40.VidarssonG.DekkersG.RispensT.IgG subclasses"/>
  <result pre="59.RajasekaranN.ChesterC.YonezawaA.ZhaoX.KohrtH.E.Enhancement of antibody-dependent cell mediated cytotoxicity: A new era in" exact="cancer" post="treatmentImmuno Targets Ther.201549110010.2147/ITT.S61292 60.KramskiM.SchorchtA.JohnstonA.P.LichtfussG.F.JegaskandaS.De RoseR.StratovI.KelleherA.D.FrenchM.A.CenterR.J.et al.Role of monocytes in"/>
  <result pre="an Fc-Dependent MannerMBio2016710.1128/mBio.01624-16 62.BarkerE.ReisfeldR.A.A mechanism for neutrophil-mediated lysis of human" exact="neuroblastoma" post="cellsCancer Res.1993533623678417829 63.AckermanM.E.MoldtB.WyattR.T.DugastA.S.McAndrewE.TsoukasS.JostS.BergerC.T.SciaranghellaG.LiuQ.et al.A robust, high-throughput assay to determine"/>
  <result pre="cell-mediated cytotoxicity epitopes on the hemagglutinin antigen of pandemic H1N1" exact="influenza" post="virusJ. Virol.2013875831584010.1128/JVI.00273-1323487456 71.YeZ.W.YuanS.PoonK.M.WenL.YangD.SunZ.LiC.HuM.ShuaiH.ZhouJ.et al.Antibody-Dependent Cell-Mediated Cytotoxicity Epitopes on the"/>
  <result pre="CytoxicityJ. Infect. Dis.201721731110.1093/infdis/jix54629294018 74.ChaiN.SwemL.R.ParkS.NakamuraG.ChiangN.EstevezA.FongR.KamenL.KhoE.ReicheltM.et al.A broadly protective therapeutic antibody against" exact="influenza" post="B virus with two mechanisms of actionNat. Commun.201781423410.1038/ncomms1423428102191 75.AlterG.MalenfantJ.M.AltfeldM.CD107a"/>
  <result pre="antibodies binding to H4 hemagglutinin protect against a lethal H4N6" exact="influenza" post="virus challenge in the mouse modelEmerg. Microbes Infect.2019815516810.1080/22221751.2018.156436930866770 82.CoxF.KwaksT.BrandenburgB.KoldijkM.H.KlarenV.SmalB.KorseH.J.GeelenE.TetteroL.ZuijdgeestD.et"/>
  <result pre="plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against" exact="influenza" post="A virusProc. Natl. Acad. Sci. USA2016113119311193610.1073/pnas.160931611327698132 84.ErmlerM.E.KirkpatrickE.SunW.HaiR.AmanatF.ChromikovaV.PaleseP.KrammerF.Chimeric Hemagglutinin Constructs"/>
  <result pre="high density hemagglutinin protein microarray to determine the breadth of" exact="influenza" post="antibody responsesBiotechniques20135434534810.2144/00011404123750544 89.DreyfusC.LaursenN.S.KwaksT.ZuijdgeestD.KhayatR.EkiertD.C.LeeJ.H.MetlagelZ.BujnyM.V.JongeneelenM.et al.Highly conserved protective epitopes on influenza"/>
  <result pre="of influenza antibody responsesBiotechniques20135434534810.2144/00011404123750544 89.DreyfusC.LaursenN.S.KwaksT.ZuijdgeestD.KhayatR.EkiertD.C.LeeJ.H.MetlagelZ.BujnyM.V.JongeneelenM.et al.Highly conserved protective epitopes on" exact="influenza" post="B virusesScience20123371343134810.1126/science.122290822878502 90.EkiertD.C.FriesenR.H.BhabhaG.KwaksT.JongeneelenM.YuW.OphorstC.CoxF.KorseH.J.BrandenburgB.et al.A highly conserved neutralizing epitope on"/>
  <result pre="virusesScience20123371343134810.1126/science.122290822878502 90.EkiertD.C.FriesenR.H.BhabhaG.KwaksT.JongeneelenM.YuW.OphorstC.CoxF.KorseH.J.BrandenburgB.et al.A highly conserved neutralizing epitope on group 2" exact="influenza" post="A virusesScience201133384385010.1126/science.120483921737702 91.WangT.T.TanG.S.HaiR.PicaN.PetersenE.MoranT.M.PaleseP.Broadly protective monoclonal antibodies against H3 influenza"/>
  <result pre="2 influenza A virusesScience201133384385010.1126/science.120483921737702 91.WangT.T.TanG.S.HaiR.PicaN.PetersenE.MoranT.M.PaleseP.Broadly protective monoclonal antibodies against H3" exact="influenza" post="viruses following sequential immunization with different hemagglutininsPLoS Pathog.20106e100079610.1371/journal.ppat.100079620195520 92.YasugiM.Kubota-KoketsuR.YamashitaA.KawashitaN.DuA.SasakiT.NishimuraM.MisakiR.KuharaM.BoonsathornN.et"/>
  <result pre="different hemagglutininsPLoS Pathog.20106e100079610.1371/journal.ppat.100079620195520 92.YasugiM.Kubota-KoketsuR.YamashitaA.KawashitaN.DuA.SasakiT.NishimuraM.MisakiR.KuharaM.BoonsathornN.et al.Human monoclonal antibodies broadly neutralizing against" exact="influenza" post="B virusPLoS Pathog.20139e100315010.1371/journal.ppat.100315023408886 93.LangS.XieJ.ZhuX.WuN.C.LernerR.A.WilsonI.A.Antibody 27F3 Broadly Targets Influenza A"/>
  <result pre="plasma cells that binds to group 1 and group 2" exact="influenza" post="A hemagglutininsScience201133385085610.1126/science.120566921798894 95.EkiertD.C.BhabhaG.ElsligerM.A.FriesenR.H.JongeneelenM.ThrosbyM.GoudsmitJ.WilsonI.A.Antibody recognition of a highly conserved influenza"/>
  <result pre="2 influenza A hemagglutininsScience201133385085610.1126/science.120566921798894 95.EkiertD.C.BhabhaG.ElsligerM.A.FriesenR.H.JongeneelenM.ThrosbyM.GoudsmitJ.WilsonI.A.Antibody recognition of a highly conserved" exact="influenza" post="virus epitopeScience200932424625110.1126/science.117149119251591 96.LaursenN.S.WilsonI.A.Broadly neutralizing antibodies against influenza virusesAntivir. Res.20139847648310.1016/j.antiviral.2013.03.02123583287"/>
  <result pre="a highly conserved influenza virus epitopeScience200932424625110.1126/science.117149119251591 96.LaursenN.S.WilsonI.A.Broadly neutralizing antibodies against" exact="influenza" post="virusesAntivir. Res.20139847648310.1016/j.antiviral.2013.03.02123583287 97.KrammerF.Novel universal influenza virus vaccine approachesCurr. Opin."/>
  <result pre="epitopeScience200932424625110.1126/science.117149119251591 96.LaursenN.S.WilsonI.A.Broadly neutralizing antibodies against influenza virusesAntivir. Res.20139847648310.1016/j.antiviral.2013.03.02123583287 97.KrammerF.Novel universal" exact="influenza" post="virus vaccine approachesCurr. Opin. Virol.2016179510310.1016/j.coviro.2016.02.00226927813 98.NachbagauerR.KinzlerD.ChoiA.HirshA.BeaulieuE.LecrenierN.InnisB.L.PaleseP.MallettC.P.KrammerF.A chimeric haemagglutinin-based influenza"/>
  <result pre="universal influenza virus vaccine approachesCurr. Opin. Virol.2016179510310.1016/j.coviro.2016.02.00226927813 98.NachbagauerR.KinzlerD.ChoiA.HirshA.BeaulieuE.LecrenierN.InnisB.L.PaleseP.MallettC.P.KrammerF.A chimeric haemagglutinin-based" exact="influenza" post="split virion vaccine adjuvanted with AS03 induces protective stalk-reactive"/>
  <result pre="with AS03 induces protective stalk-reactive antibodies in miceNPJ Vaccines2016111010.1038/npjvaccines.2016.15 99.NachbagauerR.KrammerF.Universal" exact="influenza" post="virus vaccines and therapeutic antibodiesClin. Microbiol. Infect.20172322222810.1016/j.cmi.2017.02.00928216325 100.DiLilloD.J.PaleseP.WilsonP.C.RavetchJ.V.Broadly neutralizing"/>
  <result pre="in vivo protectionJ. Clin. Investig.201612660561010.1172/JCI8442826731473 101.BrandenburgB.KoudstaalW.GoudsmitJ.KlarenV.TangC.BujnyM.V.KorseH.J.KwaksT.OtterstromJ.J.JuraszekJ.et al.Mechanisms of hemagglutinin targeted" exact="influenza" post="virus neutralizationPLoS ONE20138e8003410.1371/journal.pone.008003424348996 102.BangaruS.ZhangH.GilchukI.M.VossT.G.IrvingR.P.GilchukP.MattaP.ZhuX.LangS.NieusmaT.et al.A multifunctional human monoclonal neutralizing"/>
  <result pre="monoclonal neutralizing antibody that targets a unique conserved epitope on" exact="influenza" post="HANat. Commun.20189266910.1038/s41467-018-04704-929991715 103.WatanabeA.McCarthyK.R.KuraokaM.SchmidtA.G.AdachiY.OnoderaT.TonouchiK.CaradonnaT.M.BajicG.SongS.et al.Antibodies to a Conserved Influenza Head"/>
  <result pre="Domain Trimer InterfaceCell20191771136115210.1016/j.cell.2019.04.01131100268 105.LeonP.E.HeW.MullarkeyC.E.BaileyM.J.MillerM.S.KrammerF.PaleseP.TanG.S.Optimal activation of Fc-mediated effector functions by" exact="influenza" post="virus hemagglutinin antibodies requires two points of contactProc. Natl."/>
  <result pre="multimechanistic antibody targeting the receptor binding site potently cross-protects against" exact="influenza" post="B virusesSci. Transl. Med.2017910.1126/scitranslmed.aam575229046433 107.MostafaA.PleschkaS.Influenza H3N2 Vaccines: Recent ChallengesTrends"/>
  <result pre="Transl. Med.2017910.1126/scitranslmed.aam575229046433 107.MostafaA.PleschkaS.Influenza H3N2 Vaccines: Recent ChallengesTrends Microbiol.201826878910.1016/j.tim.2017.12.00329268980 108.NeirynckS.DerooT.SaelensX.VanlandschootP.JouW.M.FiersW.A universal" exact="influenza" post="A vaccine based on the extracellular domain of the"/>
  <result pre="domain of the M2 proteinNat. Med.199951157116310.1038/1348410502819 109.SchotsaertM.De FiletteM.FiersW.SaelensX.Universal M2 ectodomain-based" exact="influenza" post="A vaccines: Preclinical and clinical developmentsExpert Rev. Vaccines2009849950810.1586/erv.09.619348565 110.EichelbergerM.C.MontoA.S.Neuraminidase,"/>
  <result pre="recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against" exact="influenza" post="virus infection in miceMBio20156e0255610.1128/mBio.02556-1425759506 112.WohlboldT.J.KrammerF.In the shadow of hemagglutinin:"/>
  <result pre="miceMBio20156e0255610.1128/mBio.02556-1425759506 112.WohlboldT.J.KrammerF.In the shadow of hemagglutinin: A growing interest in" exact="influenza" post="viral neuraminidase and its role as a vaccine antigenViruses201462465249410.3390/v606246524960271"/>
  <result pre="al.Broadly protective human antibodies that target the active site of" exact="influenza" post="virus neuraminidaseScience201936649950410.1126/science.aay067831649200 114.CadyS.D.LuoW.HuF.HongM.Structure and function of the influenza A"/>
  <result pre="site of influenza virus neuraminidaseScience201936649950410.1126/science.aay067831649200 114.CadyS.D.LuoW.HuF.HongM.Structure and function of the" exact="influenza" post="A M2 proton channelBiochemistry2009487356736410.1021/bi900883719601584 115.PielakR.M.ChouJ.J.Influenza M2 proton channelsBiochim. Biophys."/>
  <result pre="RooijenN.VerbeekS.FiersW.SaelensX.Universal vaccine based on ectodomain of matrix protein 2 of" exact="influenza" post="A: Fc receptors and alveolar macrophages mediate protectionJ. Immunol.20111861022103110.4049/jimmunol.090214721169548"/>
  <result pre="receptors and alveolar macrophages mediate protectionJ. Immunol.20111861022103110.4049/jimmunol.090214721169548 118.LeeY.T.KimK.H.KoE.J.LeeY.N.KimM.C.KwonY.M.TangY.ChoM.K.LeeY.J.KangS.M.New vaccines against" exact="influenza" post="virusClin. Exp. Vaccine Res.20143122810.7774/cevr.2014.3.1.1224427759 119.SchepensB.De VliegerD.SaelensX.Vaccine options for influenza:"/>
  <result pre="antibodies but plays a critical role in conferring protection after" exact="influenza" post="M2 vaccinationImmunology201414330030910.1111/imm.1231024773389 121.KolpeA.SchepensB.FiersW.SaelensX.M2-based influenza vaccines: Recent advances and clinical"/>
  <result pre="critical role in conferring protection after influenza M2 vaccinationImmunology201414330030910.1111/imm.1231024773389 121.KolpeA.SchepensB.FiersW.SaelensX.M2-based" exact="influenza" post="vaccines: Recent advances and clinical potentialExpert Rev. Vaccines20171612313610.1080/14760584.2017.124004127653543 122.SongA.MyojoK.LaudenslagerJ.HaradaD.MiuraT.SuzukiK.Kuni-KamochiR.SoloffR.OhgamiK.KandaY.Evaluation"/>
  <result pre="Vaccines20171612313610.1080/14760584.2017.124004127653543 122.SongA.MyojoK.LaudenslagerJ.HaradaD.MiuraT.SuzukiK.Kuni-KamochiR.SoloffR.OhgamiK.KandaY.Evaluation of a fully human monoclonal antibody against multiple" exact="influenza" post="A viral strains in mice and a pandemic H1N1"/>
  <result pre="primatesAntivir. Res.2014111606810.1016/j.antiviral.2014.08.01625218949 123.VirelizierJ.L.AllisonA.C.OxfordJ.S.SchildG.C.Early presence of ribonucleoprotein antigen on surface of" exact="influenza" post="virus-infected cellsNature1977266525410.1038/266052a0840296 124.YewdellJ.W.FrankE.GerhardW.Expression of influenza A virus internal antigens"/>
  <result pre="ribonucleoprotein antigen on surface of influenza virus-infected cellsNature1977266525410.1038/266052a0840296 124.YewdellJ.W.FrankE.GerhardW.Expression of" exact="influenza" post="A virus internal antigens on the surface of infected"/>
  <result pre="surface of infected P815 cellsJ. Immunol.1981126181418197217668 125.AntrobusR.D.LillieP.J.BerthoudT.K.SpencerA.J.McLarenJ.E.LadellK.LambeT.MilicicA.PriceD.A.HillA.V.et al.A T cell-inducing" exact="influenza" post="vaccine for the elderly: Safety and immunogenicity of MVA-NP+M1"/>
  <result pre="in adults aged over 50 yearsPLoS ONE20127e4832210.1371/journal.pone.004832223118984 126.ZhengM.LuoJ.ChenZ.Development of universal" exact="influenza" post="vaccines based on influenza virus M and NP genesInfection20144225126210.1007/s15010-013-0546-424178189"/>
  <result pre="50 yearsPLoS ONE20127e4832210.1371/journal.pone.004832223118984 126.ZhengM.LuoJ.ChenZ.Development of universal influenza vaccines based on" exact="influenza" post="virus M and NP genesInfection20144225126210.1007/s15010-013-0546-424178189 127.BerthoudT.K.HamillM.LillieP.J.HwendaL.CollinsK.A.EwerK.J.MilicicA.PoyntzH.C.LambeT.FletcherH.A.et al.Potent CD8+ T-cell"/>
  <result pre="al.Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic" exact="influenza" post="A vaccine, MVA-NP+M1Clin. Infect. Dis.2011521710.1093/cid/ciq01521148512 128.JegaskandaS.CoM.D.T.CruzJ.SubbaraoK.EnnisF.A.TerajimaM.Induction of H7N9-Cross-Reactive Antibody-Dependent"/>
  <result pre="role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to" exact="influenza" post="virusJ. Immunol.20081814168417610.4049/jimmunol.181.6.416818768874 130.FlorekN.W.WeinfurterJ.T.JegaskandaS.BrewooJ.N.PowellT.D.YoungG.R.DasS.C.HattaM.BromanK.W.HungnesO.et al.Modified vaccinia virus Ankara encoding influenza"/>
  <result pre="nucleoprotein in facilitating resistance to influenza virusJ. Immunol.20081814168417610.4049/jimmunol.181.6.416818768874 130.FlorekN.W.WeinfurterJ.T.JegaskandaS.BrewooJ.N.PowellT.D.YoungG.R.DasS.C.HattaM.BromanK.W.HungnesO.et al.Modified" exact="vaccinia virus" post="Ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in"/>
  <result pre="to influenza virusJ. Immunol.20081814168417610.4049/jimmunol.181.6.416818768874 130.FlorekN.W.WeinfurterJ.T.JegaskandaS.BrewooJ.N.PowellT.D.YoungG.R.DasS.C.HattaM.BromanK.W.HungnesO.et al.Modified vaccinia virus Ankara encoding" exact="influenza" post="virus hemagglutinin induces heterosubtypic immunity in macaquesJ. Virol.201488134181342810.1128/JVI.01219-1425210172 131.VandervenH.A.LiuL.Ana-Sosa-BatizF.NguyenT.H.WanY.WinesB.HogarthP.M.TilmanisD.ReynaldiA.ParsonsM.S.et"/>
  <result pre="133.WangJ.LiuM.DingN.LiY.ShaoJ.ZhuM.XieZ.SunK.Vaccine based on antibody-dependent cell-mediated cytotoxicity epitope on the H1N1" exact="influenza" post="virus increases mortality in vaccinated miceBiochem. Biophys. Res. Commun.20185031874187910.1016/j.bbrc.2018.07.12930064910"/>
  <result pre="LimC.StephensonR.SalazarA.M.FerrisR.L.TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR(+)" exact="head and neck cancer" post="cellsOncoimmunology20132e2467710.4161/onci.2467723894722 138.RodaJ.M.PariharR.CarsonW.E.3rdCpG-containing oligodeoxynucleotides act through TLR9 to enhance the"/>
  <result pre="the immunostimulatory potential of cetuximab against EGFR(+) head and neck" exact="cancer" post="cellsOncoimmunology20132e2467710.4161/onci.2467723894722 138.RodaJ.M.PariharR.CarsonW.E.3rdCpG-containing oligodeoxynucleotides act through TLR9 to enhance the"/>
  <result pre="of a Universal Influenza VaccineVaccines201862710.3390/vaccines602002729772781 144.KosikI.AngelettiD.GibbsJ.S.AngelM.TakedaK.KosikovaM.NairV.HickmanH.D.XieH.BrookeC.B.et al.Neuraminidase inhibition contributes to" exact="influenza" post="A virus neutralization by anti-hemagglutinin stem antibodiesJ. Exp. Med.201921630431610.1084/jem.2018162430683737"/>
  <result pre="Exp. Med.201921630431610.1084/jem.2018162430683737 145.DengL.MohanT.ChangT.Z.GonzalezG.X.WangY.KwonY.M.KangS.M.CompansR.W.ChampionJ.A.WangB.Z.Double-layered protein nanoparticles induce broad protection against divergent" exact="influenza" post="A virusesNat. Commun.2018935910.1038/s41467-017-02725-429367723 Figure 1 Schematic view of influenza"/>
  <result pre="divergent influenza A virusesNat. Commun.2018935910.1038/s41467-017-02725-429367723 Figure 1 Schematic view of" exact="influenza" post="virion. Hemagglutinin (HA), neuraminidase (NA) and matrix protein 2"/>
  <result pre="The matrix protein (M1) is a multi-functional protein involved in" exact="influenza" post="virion assembly and infection. Figure 2 Antibody-dependent cellular cytotoxicity"/>
  <result pre="epitopes [100]. Figure 4 ADCC- mediating antibodies (ADCC-Abs) targeting different" exact="influenza" post="antigens. HA, NA and M2 are the surface-exposed proteins"/>
 </snippets>
</snippetsTree>
